MedTrace Logo

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

NCT03881059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2022-02-15

Study results available
· View outcomes & findings →

Summary

The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.

Conditions

Interventions

OTHER

BMS-986165 Placebo

Participants will receive BMS-986165 matching placebo QD

DRUG

BMS-986165 Dose A

Participants will receive BMS-986165 Dose A QD.

DRUG

BMS-986165 Dose B

Participants will receive BMS-986165 dose B QD.

DRUG

Ustekinumab

Participants will receive ustekinumab SQ injection QD.

OTHER

Ustekinumab Placebo

Participants will receive ustekinumab SQ matching placebo QD

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-04-27
Completion
2021-01-27
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Germany
  • Hungary
  • Italy
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881059 on ClinicalTrials.gov